The Patent Finder

EnGeneIC Molecular Delivery Pty Ltd

20 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 5 name spellings.

7
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 25, 2026
    The maintenance fee for Enhanced loading of intact, bacterially derived vesicles with small molecule compounds (US 10,328,159) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
  • 1 fee due Jun 10, 2027
    The maintenance fee for Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma (US 10,500,277) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
  • 1 fee due Oct 23, 2027
    The maintenance fee for Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors (US 11,964,021) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,867,785Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,591,862Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,169,495Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,357,860Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,147,883Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,691,963Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,878,043Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,994,014Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,964,021Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,731,011Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 20 patents shown.
Pro members see all 20.
Pro members: see all 20 patents
Also on record, not counted in the 20: 1 lapsed for an unpaid fee · 17 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 4 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited